Back to Search
Start Over
Burkitt lymphoma – no impact of HIV status on outcomes with rituximab-based chemoimmunotherapy.
- Source :
-
Leukemia & Lymphoma . Mar2023, Vol. 64 Issue 3, p586-596. 11p. - Publication Year :
- 2023
-
Abstract
- We analyzed the prognostic factors for treatment outcomes amongst 34 patients with adult Burkitt lymphoma (BL) who received rituximab with standard first-line chemotherapy. Seven patients had human immunodeficiency virus (HIV)-associated BL. Overall, we observed a complete remission (CR) rate of 91.2%, and 10-year progression-free survival (PFS) and overall survival (OS) was 84.8 and 88.2%, respectively. In patients with concomitant HIV, the prognosis was not different with 10-year PFS of 100% and OS of 88.2%. The majority (71.4%) of HIV-associated BL patients received dose-adjusted EPOCH-R (etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab) and had excellent outcomes with 100% CR and no relapses. Central nervous system (CNS) disease, bone marrow involvement and elevated serum lactate dehydrogenase (LDH) levels more than 3 times upper limit of normal (ULN) were associated with poorer survival outcomes. Patients with refractory disease, whilst uncommon (n = 4), had dismal outcomes. Patients with adult BL, including HIV-related cases, harbor generally good prognosis in the modern era. [ABSTRACT FROM AUTHOR]
- Subjects :
- *HIV status
*HIV
*CENTRAL nervous system
*BONE marrow
*LYMPHOMAS
Subjects
Details
- Language :
- English
- ISSN :
- 10428194
- Volume :
- 64
- Issue :
- 3
- Database :
- Academic Search Index
- Journal :
- Leukemia & Lymphoma
- Publication Type :
- Academic Journal
- Accession number :
- 162636181
- Full Text :
- https://doi.org/10.1080/10428194.2022.2027402